The tuberculostatic action of vitamin D2

1952 ◽  
Vol 18 (1) ◽  
pp. 217-226 ◽  
Author(s):  
W. Klip
Keyword(s):  
Vitamin D2 ◽  
Tuberculostatic Action

scholarly journals P136 Vegan orthopaedics

BJS Open ◽  
2021 ◽  
Vol 5 (Supplement_1) ◽  
Author(s):  
Gwithyen Silk ◽  
Niraj Vetherajan ◽  
Alice Blohm ◽  
Katie Keen ◽  
Fiona Teeling ◽  
...  
Keyword(s):  
Ethnic Diversity ◽  
Informed Choice ◽  
Pharmaceutical Companies ◽  
Vitamin D2 ◽  
World Religions ◽  
Animal Products ◽  
Animal Source ◽  
Specific Manner ◽  
Prescribed Medicines ◽  
The Uk

Abstract Introduction Bristol is the vegan capital of the UK. The UK vegan index reveals that Bristol has 360,000 Google searches each month for Vegan content. However, do we think about the possible animal source of the medications we prescribe. Although all medications in the UK need to be tested on animals prior to being licensed and therefore cannot be truly “vegan”, there are alternatives available for some commonly used medications that do not contain animal products. Several world religions prohibit their followers from consuming certain foods, ranging from those not prepared in a specific manner to those derived from certain animals. Kosher and halal diet adherents share concerns with those on vegan diets. Vegan options are a solution when only non-conforming or uncertain products are available. Methods We conducted a review of commonly used medications in Orthopaedics and reviewed their source. The BNF, local pharmacy and online Summary of Product Characteristics (SPCs) for the medications were reviewed. Results Where possible we have compiled a list of those that contain animal derived components and suggest alternatives. Sometimes, pharmaceutical companies cannot guarantee or differentiate the specific sources of animal-derived ingredients, as various suppliers are used in the manufacturing process and the sources can change. All unfractionated or standard heparin is porcine in origin; Rivaroxaban and Fondaparinux are simple alternatives for example. Cholecalciferol (vitamin D3) – Manufacture also involves the use of lanolin from sheep’s wool. Vitamin D2 (ergocalciferol) is vegan. Conclusion Disclosure of animal content and excipients would help patients make an informed choice. With an increasingly informed population and ethnic diversity, we should all be aware of the drugs that may contain animal products so that we can offer alternatives. Patients are more likely to adhere to prescribed medicines if they have been actively involved in prescribing decisions.

scholarly journals The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Wareeporn Disphanurat ◽  
Wongsiya Viarasilpa ◽  
Panlop Chakkavittumrong ◽  
Padcha Pongcharoen
Keyword(s):  
Vitamin D ◽  
Placebo Group ◽  
Adverse Events ◽  
Clinical Effect ◽  
Vitamin D Supplementation ◽  
P Value ◽  
Vitamin D2 ◽  
Oral Vitamin ◽  
Pasi Score ◽  
The Mean

Background. There are limited randomized controlled trials of oral vitamin D supplementation in psoriasis, especially in Asia, and the results are inconclusive. Objective. To investigate the clinical effect of oral vitamin D supplementation on psoriasis. Methods. Patients with psoriasis were randomized to receive vitamin D2 60,000 IU or similar-looking placebo pills once every 2 weeks for 6 months. The primary outcome was improvement of the Psoriasis Area and Severity Index (PASI) score at 3 and 6 months after treatment. Serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone, and C-reactive protein and adverse events were monitored. The chi-square test, Fisher’s exact test, Student’s t-test, and Spearman’s correlation analysis were used in statistical analysis. Results. Of 50 subjects screened, 45 were eligible and randomized to the oral vitamin D2 group (n=23) or placebo group (n=22). At enrollment, the mean PASI score was 4.45, and 26.7% of patients had vitamin D deficiency. At 3 months, the oral vitamin D2 group had significantly higher PASI improvement than the placebo group (mean PASI improvement: 1.43 versus [vs.] -0.33, p-value=0.034; mean %PASI improvement: 34.21% vs. -1.85%, p-value=0.039). The mean serum 25(OH)D level was significantly higher in the oral vitamin D group than in the placebo group (27.4 vs. 22.4 ng/mL, p-value=0.029). Serum 25(OH)D concentrations were significantly inversely correlated with PASI scores at the 6-month follow-up. No major adverse event was observed overall. Conclusion. Oral vitamin D2 supplementation in patients with psoriasis increased the serum vitamin D level and significantly improved the treatment outcome without increasing adverse events. Trial Registration. This trial is registered with Thai Clinical Trials Registry TCTR20180613001.

Stability and Photochemistry of Vitamin D2 in Model System

1998 ◽  
Vol 63 (3) ◽  
pp. 413-417 ◽  
Author(s):  
TSUNG-LIN LI ◽  
DAVID B. MIN
Keyword(s):  
Model System ◽  
Vitamin D2

Gas chromatographic study of steroids in the production of vitamin D2

1969 ◽  
Vol 3 (1) ◽  
pp. 31-32
Author(s):  
M. Ts. Yanotovskii ◽  
N. A. Bogoslovskii ◽  
E. N. Kuznetsova
Keyword(s):  
Chromatographic Study ◽  
Vitamin D2
Sign in / Sign up

Export Citation Format

Share Document